|
Active substance |
risdiplam |
|
Holder |
Roche |
|
Status |
closed |
|
Indication |
Spinal Muscular Atrophy Type 2 for patients ≥ 2 months |
|
Public documents |
|
|
Last update |
11/08/2022 |
Risdiplam
Last updated on 11/08/2022